Home › Sistema ng Imunidad at mga Karamdaman › California
Pag-aaral pangklinika para sa Sistema ng Imunidad at mga Karamdaman sa California
18 pag-aaral para sa Sistema ng Imunidad at mga Karamdaman ang naghahanap ng mga kalahok sa mga site sa California.
Mga Lungsod sa California
- Los Angeles8 pag-aaral
- Baldwin Park5 pag-aaral
- San Diego3 pag-aaral
- Mountain View3 pag-aaral
- San Francisco3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- City of Hope, Duarte
- University of California, Irvine Medical Center - Hematology/Oncology, Orange
- Stanford University School of Medicine, Stanford
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07192471A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Chula Vista
Nagre-recruitPhase 2
Edad 18 hanggang 60 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07541287A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- PCR Oncology, Arroyo Grande
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
- Washington Health, Fremont
- at 3 pa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04242095(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- City of Hope Comprehensive Cancer Center, Duarte
- UCLA Medical Center, Los Angeles
- Stanford Cancer Institute, Stanford
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04996875A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- USC Norris Comprehensive Cancer Center - Keck Medicine of USC, Los Angeles
- University of California San Diego Center for Bleeding and Clotting Disorders, San Diego
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06948318A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- Northridge Clinical Trials, Northridge
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07765888A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
- City of Hope, Duarte
- Stanford University, Palo Alto
- UCSF, San Francisco
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07075185Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of California-Irvine Medical Center, Irvine
- Cedars-Sinai Medical Center, Los Angeles
- University of California, Los Angeles (UCLA) Medical Center, Los Angeles
- at 1 pa
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 1, Lancaster
- Inmagene Site 23, Los Angeles
Nagre-recruitPhase 2
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT07037901Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- UCLA Department of Medicine, Los Angeles
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 7, 2026 · NCT07216443Atacicept in Multiple Glomerular Diseases
- Vera Therapeutics, Brisbane
Nagre-recruitPhase 2
Edad 2 pataas · Lahat ng kasarian · Na-update Hun 26, 2026 · NCT06983028A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- University of California, San Francisco, San Francisco
Nagre-recruitPhase 2
Lahat ng edad · Lahat ng kasarian · Na-update Hun 2, 2026 · NCT05787574A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- Stanford University, Dept. of Dermatology, Redwood City
- UC Davis, Dept. of Dermatology, Sacramento
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update May 29, 2026 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- City of Hope, Duarte
- Providence St. John's Health Center, Santa Monica
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 16, 2026 · NCT03328078Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers
- USC / Norris Comprehensive Cancer Center, Los Angeles
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 pataas · Lahat ng kasarian · Na-update Abr 2, 2026 · NCT03207854A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- City of Hope National Medical Center, Duarte
- Ronald Regan UCLA Medical Center, Los Angeles
- University of California Irvine Health, Orange
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 15, 2025 · NCT06619561Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
- Southern California Hospital at Culver City / Southern California Hospital at Hollywood / Multiple US-based Sub-Investigator Sites, Culver City
Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 29, 2022 · NCT04684602Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.